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Abstract
The molecular mechanisms for the discrepancy in outcome of initiating estrogen therapy (ET) around peri-menopause or
several years after menopause in women are unknown. We hypothesize that the level of expression of a dominant negative
estrogen receptor (ER) b variant, ERb2, may be a key factor determining the effectiveness of ET in post-menopausal women.
We tested this hypothesis in ovariectomized nine month-old (an age when irregular estrous cycles occur) female Sprague
Dawley rats. Estradiol treatment was initiated either 6 days (Early ET, analogous to 4 months post-menopause in humans), or
180 days (Late ET, analogous to 11 years post-menopause in humans) after ovariectomy. Although ERb2 expression
increased in all OVX rats, neurogenic and neuroprotective responses to estradiol differed in Early and Late ET. Early ET
reduced ERb2 expression in both hippocampus and white blood cells, increased the hippocampal cell proliferation as
assessed by Ki-67 expression, and improved mobility in the forced swim test. Late ET resulted in either no or modest effects
on these parameters. There was a close correlation between the degree of ERb2 expression and the preservation of neural
effects by ET after OVX in rats, supporting the hypothesis that persistent elevated levels of ERb2 are a molecular basis for the
diminished effectiveness of ET in late post-menopausal women. The correlation between the expression of ERb2i n
circulating white blood cells and brain cells suggests that ERb2 expression in peripheral blood cells may be an easily
accessible marker to predict the effective window for ET in the brain.
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Introduction
Most women in developed countries now live 25 to 30 years,
one third of their lives, after menopause, during which time they
are at increased risk for cardiovascular disease, osteoporosis and
dementia. Research into the etiology of menopausal dementia
leading to the development of effective prevention and therapeutic
strategies, will thereby improve women’s overall health and quality
of life, and significantly reduce the public healthcare burden.
Basic science studies and observational trials [1–6] suggested
that estrogen therapy (ET) would prevent cognitive decline
associated with menopause, however, this was challenged by the
results from the Women’s Health Initiative and the ancillary
Memory Study (WHIMS) in 2002 [7,8]. Among reasons cited for
the discrepancy were differences in the type of estrogenic
compounds used, routes of administration, cyclic versus continu-
ous regimens, concomitant use of progestins, and the time after
menopause that the ET was initiated. The latter led to the
hypothesis of a critical period, or therapeutic window, during
which ET must be initiated to obtain maximum benefit [1,5,9,10].
To date, the molecular basis of this hypothesis and the boundaries
of the clinical therapeutic window are unknown.
Many of the effects of estrogens are mediated by estrogen
receptors (ER), primarily ERa and ERb, which are encoded by
different genes. Both ERa and ERb are expressed in the brain.
ERb is thought to be more important in sleep disturbance,
irritability, depression and anxiety, panic disorders, and cognitive
dysfunction [11–16]. The ERb transcripts are spliced into different
mRNAs and translated into ERb variants with different biological
functions depending physiological or pathological conditions. One
of these, hERb2/hERbcx found in humans and non-human
primates, contains unique 26 amino acid (aa) residues which
replace the aa residues encoded from exon 8 in the C-terminal
part of the ligand binding domain. hERb2 forms dimers with
other ER, but is unable to bind ligands or coactivators and has no
transcriptional activity in reporter assays[17,18]. Ectopic expres-
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33493sion of hERb2 inhibits ERa-mediated gene transcription and cell
proliferation in vitro in MCF cells [19]. Hence it is considered a
dominant negative isoform. Swaab’s group has demonstrated the
expression of the alternatively spliced ERa mRNAs in post-
mortem brain of Alzheimer’s Disease and that the dominant
negative deletion (del.) 7 isoform appeared to be the major splice
variant [20].
Several ERb splice variants have been identified in the rat
hippocampus. One of these, rERb2, has an additional 54 bp
nucleotides coding for extra 18 amino acids within the ligand
binding domain that changes the conformation and reduces the
binding affinity of rERb2 to estradiol by up to 30-fold [21,22]. In
addition, rERb2 also exhibits weaker interactions with TIF2 and
RAP250, two transcription coactivators [21,22]. The low binding
affinity to estradiol and the ability to interact with coactivators
make rERb2 a dominant negative receptor in the rat [23,24].
Therefore, although the rERb2 and hERb2 do not share the same
spliced aa residues, both differ from ERb in the C-terminal ligand
binding domain, both result in diminished ligand binding and both
preferentially dimerize with ERa, decreasing normal ER-mediated
functions [19].
It has been reported that ERb2 levels increase in the
hippocampus [25,26], and pituitary [27] of OVX rats. This shift
to prominent expression of the dominant negative receptor is
reversible while there are still enough functional ERb, but at some
yet to be defined point, the level of ERb2 expression disrupts
normal ERb activity. We hypothesize that ERb2 expression
increases with the duration of gonadal hormone deprivation and
that the point at which ERb2 levels disrupt ER-mediated functions
is the molecular mechanism underlying the closing of the
therapeutic window for estrogen therapy. To test this hypothesis,
rats were ovariectomized at 9 months of age and studied after
Early ET (E2 treatment starting 6 days after OVX, equivalent to
human early post-menopause [28,29]) and Late ET (E2 treatment
starting 180 days after OVX, equivalent to starting 10–20 years
after menopause, as was done in the WHIMS trial). ERb2 levels in
peripheral blood cells were compared to those in the brain to
determine whether these could be a valid marker for ERb2
expression in the brain.
Materials and Methods
Animal and treatments
The animal protocol (#1168) was approved by the University of
Mississippi Medical Center Animal Care and Use Committee and
conformed to National Institutes of Health guidelines. UMMC is
an AAALAC accredited facility. Six month old female or retired
breeder (9 month-old) Sprague-Dawley rats were purchased from
Charles River (Harlan Laboratories, Indianapolis, IN) and were
housed and maintained on a 12/12-hour light/dark cycle (lights
on 7:00 AM) and provided with unlimited access to food and water
in the Laboratory Animal Facilities at the University Mississippi
Medical Center.
Ovariectomy
The rats were anaesthetized with ketamine (100 mg/kg) and
xylazine (10 mg/kg). The incision sites were shaved and cleansed
with povidone iodine solution. Standard aseptic procedures were
observed. Dorsal incisions were made in the lumbar region to
reveal the dorsal fat pads covering the ovaries. Ovaries were
removed after compression of the ovarian pedicle. After
ovariectomy, the incisions were sutured. Rats were given
Carprofen (subcutaneous, 5 mg/kg, once/day for 2 days), and
returned to home cages for the number of days required by the
experiment at which time they received E2 or vehicle injections.
Groups
The effects of removing ovarian hormones on the expression of
ERb and ERb2 were first evaluated in adult reproductive (6
month-old) naı ¨ve, sham OVX and OVX rats 14 days after
surgery. Rats begin to show irregular estrous cycles at 9–12
months, as defined by prolonged cycles, interspersed with the
normal 4–5 days rhythm [28,29]. As aging occurs, these animals
transition into an acyclic, persistent anestrus status, in which
ovulation has ceased [28,29] at 15 to 23 months of age. Therefore,
in order to further study the role of ERb2 in Early and Late ET in
post-menopausal females, female Sprague-Dawley rats, at 9
months old (compatible to human perimenopause), were ovariec-
tomized (OVX, a rodent menopausal model) or sham-OVX.
Estradiol treatments were initiated on day 7 (Early ET) or day 181
(Late ET) after OVX (Figure 1). In both Early and Late ET
cohorts, 8 rats were sham-OVX, and 17 were OVX. Of the 17
OVX rats, 9 were treated with estradiol, while the other 8 were
received vehicle.
Treatment
Rats were subcutaneously injected with estradiol, 30 mg/kg
body weight or vehicle for 5 days (once per day). Although it has
been reported by Tanapat that 10 mg/kg, but not 50 mg/kg, was
the best concentration for promoting the proliferation of neural
progenitor cells in the SGZ in OVX female rat hippocampus [30],
the effects of estradiol at the doses between 10 and 50 mg/kg were
not reported. In our previous dose response studies, we found that
the concentration of 30 mg/kg estradiol showed the highest effects
on neuroprotection and neurogenesis [16,31]. One day after the
last estradiol injection, rats were assigned for a forced swim test
(5 minutes) in random order. Animals were humanely sacrificed 7
days after the first estradiol injection and leukocytes, plasma,
uterus, and brain were collected. One hemisphere of the brain was
immediately dissected and several cortical regions and the
hippocampus were frozen in liquid nitrogen and stored at
280uC for mRNA and protein assay. The other hemisphere
was fixed in 4% paraformaldehyde (PFA).
FACS assay for Ki-67 positive cells
The assay was performed as previously described [32]. Briefly,
the hippocampus was extracted from the PFA fixed brain
hemispheres using consistent anatomical landmarks as criteria
for dissection as described by Bilsland [33]. The white membranes
were removed to avoid the contribution from subventricular zone
and rostral migratory stream proliferative pools. Nuclei were
extracted from the homogenate from individual hippocampus.
Figure 1. Experimental flow chart for determining the impact
of Early and Late estrogen therapy. Nine-month-old Sprague
Dawley rats were ovariectomized and estradiol treatment was initiated
6 days (Early ET) or 180 days (Late ET) after OVX. After 6 days of
treatment including two days behavioral tests, the rats were humanely
sacrificed and brain and blood samples collected.
doi:10.1371/journal.pone.0033493.g001
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boric acid, pH 9.0, and heated for 1 h at 75uC for epitope
retrieval. Subsequently, nuclei were incubated for 24 h at 4uCi n
primary antibodies (1:500 for polyclonal anti-Ki-67, abcam,
ab15580) and in CY2-conjugated goat anti-rabbit IgG secondary
antibody (1:100 in PBS; Jackson Immuno Reasearch Labs, Inc.)
for 2 h. An aliquot of the nuclear suspensions (2.5 ul) was stained
with propidium iodide (PI), a fluorescent molecule that stoichio-
metrically binds to DNA by intercalating between the bases with
no sequence preference, and checked under fluorescent micro-
scope to verify the immunolabeling quality. The remaining cell
suspension was diluted to 500 mL for flow cytometry assay using a
Beckman FC 500 System with CXP Software. To avoid counting
bias, we registered the presence or absence of Ki-67 immunore-
activity for all of the PI-stained nuclei samples until 10,000 PI-
stained nuclei were examined. Nuclear density was estimated by
counting the PI positive particles.
Extraction of leukocytes protein from whole blood
To translate the concept that ERb2 expression predicts the
effectiveness of ET into a clinically useful guideline, we measured
ERb2 expression in circulating white blood cells (WBC).
Ammonium chloride solution (0.17 M at room temperature) was
added to each blood sample in a volume 1:9 to lyse red blood cells
and the samples incubated for 5 minutes in a rotator. The red
blood cells would not be completely lysed if the solution was cold
and the white blood cells began to lyse if the incubation exceeded
5 minutes. The suspension of WBC and lysed RBCs was
centrifuged for 5 minutes at 2000 RPM. The supernatant was
discarded and the pellet washed in ice old PBS (in a volume of 10
times of that of starting blood sample) [34]. The white blood cells
were collected by 5 min centrifugation at 2000 RPM and lysed in
0.2 ml of ice cold fresh RIPA buffer. After suspension by gentle
pipetting, the lysates were set on ice for 15 minutes to increase the
total yield of soluble protein. Samples were then sonicated on a
70% setting for 30 sec to shear the DNA, incubated 30–
60 minutes on ice, centrifuged on a bench-top microcentrifuge
at 12,0006g for 15 minutes at 4uC, and the supernatant collected
into a new tube. The protein concentration was determined by the
BCA method (Pierce Biotechnology, Rockford, IL).
Western blot
Two specific antibodies were used to detect ERb and ERb2
protein. The H-150 antibody recognizes the N-terminal epitope of
rat ERb (Santa Cruz) and the ERb2 antibody (gift from Dr.
Robert Handa) recognizes the unique 18 aa residues in ERb2 and
does not cross-react with either ERb,E R a, or other ER isoforms
[25]. Thus a protein band on PVDF membrane that is positive for
both the H-150 and Handa’ antibodies reduced the possibility of a
false positive for ERb2. Antibodies for b-actin, a loading control
for cytosol protein, and histone H3, a nuclear protein loading
control, were used as internal controls. The relative quantity of
ERb and ERb2 were normalized by internal controls. The data
were collected with a Bio-Rad Molecular Imager ChemiDoc
XRS+ system and the optical density was analyzed with the Bio-
Rad image lab software.
Forced Swim Test
Rats were placed in a cylindrical container (40 cm deep, 27 cm
in diameter) filled with 30 cm of 30uC water, the 10-min test was
videoed, and the amount of time the rats spent swimming or
immobile in 10-min was analyzed. Swimming was defined as
movement of the forelimbs and hindlimbs without the front paws
breaking the surface of the water. Immobility was recorded when
there was an absence of any movement other than that necessary
to keep the head and nose above the water (when rats were
floating in a vertical position) [35,36]. Before testing, all rats were
coded and codes were not broken until the video analyses had
been completed.
Statistics
Statistically analysis was by a Two-way ANOVA followed by a
Neuman-Keuls test. In all analyses, differences were considered
significant at probability (p) values less than 0.05.
Results
Removal of ovaries increases the expression of a
dominant negative ERb splice variant, rERb2
The role of ovarian hormones on formation of the dominant
negative ERb splice variant, ERb2 (an intron retention isoform),
was first tested in hippocampus of 6 month old reproductive
female rats. The ERb specific antibody (h-150, Santa Cruz)
detected two proteins at molecular masses of 54 kDa and 57 kDa
(Figure 2A). The 57 kDa larger band is consistent with ERb2
which has an additional 18 amino acid in the ligand binding
domain of ERb. The ratio of the 57/54 kDa proteins in naı ¨ve rats
is 4.7%, in sham rats is 3.6%, and in OVX rats is 112%
(Figure 2B). To identify the 57 kDa protein band which is
recognized by ERb antibody h-150, an antibody which specifically
recognizes the 18 amino acid in ERb2, but does not cross-react
with ERb or ERa [25] was used. The 57 kDa protein band was
only recognized by the antibody against the unique 18 amino acids
in ERb2 (Figure 2C). ERb2 expression was detectable in 6 month-
old female OVX rats 15 days after OVX, but not in sham OVX
rats (Figure 2C).
Figure 2. Loss of ovarian hormones increases ERb2 expression.
Each lane was loaded with 30 mg of protein from rat hippocampus
(n=6/group). A. Western blot of ERb in hippocampus of 6 month old
rats that were naive, or sham and OVX for 14 days using h-150 ERb
antibody (Santa Cruz). B. Optical density of the expressed 54 and
57 kDa ERb immunoreactive proteins using the h-150 ERb antibody. C.
Western blot using the ERb2 antibody (gift from Dr. Handa) which
recognizes the unique 57 kDa 18 amino acid sequence in rERb2that
does not cross-react with either ERb or ERa.
doi:10.1371/journal.pone.0033493.g002
ERb2 Determines the Therapeutic Window of ET
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33493Early, but not late treatment with exogenous estradiol
decreases the OVX-evoked ERb2 expression in cortex and
hippocampus in rats
Figure 3 presents the results of the ERb2 expression in
hippocampus of 9 month old OVX female rats (OV) which were
received Early (A) or Late (B) ET (OE) and compared with that in
age matched sham OVX rats (SOV). In Early ET group, OVX
induced a significant increase (21%, * p,0.05) in ERb2
immunoreactivity in 9 month old rats within 15 days of OVX
compared to sham OVX. Six days of estradiol treatment initiated
on day 7 after OVX repressed expression of ERb2 by 45%
compared to OVX 9 month old rats receiving vehicle (#,p ,0.01)
and which was 25% lower than that in the sham OVX rats.
In Late ET group, ERb2 expression was consistently higher
(47% increase) in hippocampus of OVX rats than the sham OVX
rats (Figure 3B). Initiation of estradiol treatment 6 months after
OVX had no effect on the repression of ERb2 which was
consistently higher (42%) in hippocampus of Late ET OVX rats
compared to sham OVX rats (Figure 3B).
Duration of ovarian hormone loss and efficacy of
estradiol to increase cell proliferation in hippocampus
Ki-67 is an endogenous transient cell proliferation marker
expressed in nuclei of actively cycling cells which is not expressed
in differentiating quiescent cells. The number of Ki-67-expressing
cells was measured using flow cytometry in hippocampus of rats
that received Early and Late ET. The Ki-67 positive cells were
41% less (p,0.05) in 15 month old compared to 9.5 month old
sham OVX rats (Figure 4A), suggesting an age dependent decrease
of hippocampal cell proliferation in female rats. The number of
Ki-67 positive cells in 9 and 15 month-old OVX rats were similar
despite the different duration of ovary loss, 6 or 180 days,
suggesting that ovarian hormones have a major role in
hippocampal cell proliferation.
The number of Ki-67 positive cells in the hippocampus of rats
receiving Early ET, in which E2 treatment was initiated 6 days
after OVX, was twice than that of OVX rats not treated with E2
(p,0.01) and not significantly different from that of sham OVX
rats (p.0.26). Proliferation of hippocampal cells was not increased
in rats receiving Late ET, in which E2 treatment was initiated 180
days after OVX (p.0.36), compared to OVX vehicle control.
There was a significant difference in hippocampal cell proliferation
between the OVX rats that received Early or Late ET (p,0.01).
Figure 3. Persistent loss of ovarian hormones diminishes the
effects of estradiol on the regulation of ERb2 expression. ERb2
protein expression was evaluated by Western blot in hippocampus of
rats OVX at 9 months of age in which E2 treatment was started 6 days
(A, Early ET) or 180 days (B, Late ET) after OVX. Data is presented as
average 6 SEM of optical density normalized with optical density of b-
actin (n=8 in SOV, 8 in OV and 9 in OE. *=p,0.05 vs. sham OVX;
#=p,0.01 vs. sham OVX.
doi:10.1371/journal.pone.0033493.g003
Figure 4. Persistent loss of ovarian hormones diminishes the
response to estradiol on hippocampal cell proliferation and
duration of forced swim. The effects of estradiol on hippocampal
cell proliferation was determined by counting the number of Ki-67
positive nuclei in hippocampus (A); the antidepressant effect of
estradiol was evaluated by forced on swim test (B), in rats that received
Early or Late ET. Data is presented as average 6 SEM (n=8 in SOV, 8 in
OV and 9 in OE).
doi:10.1371/journal.pone.0033493.g004
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hippocampal cells, in rats when the estradiol was given soon after
OVX, but not after prolonged loss of ovarian hormones.
Antidepressant efficacy of estrogen therapy correlates
with the duration of ovarian hormone loss before
therapy is initiated
The forced swim test was performed to evaluate the
antidepressant effects of estradiol in Early and Late ET rats
(Figure 4B). The swim time of 15 month-old sham OVX rats was
53615 sec, 57% less than the 9-month old sham-OVX rats
(123627 sec, p,0.01). The swim time of 9 month-old rats OVX
for 6 days was 44% less than that of age-matched sham-OVX rats
(p,0.05). The swim time of rats receiving estradiol 6 days after
OVX was 153652 sec, significantly higher than that in age
matched OVX rats that received vehicle (p,0.01). OVX did not
change the swim time of 15 month old female rats and there was
no difference in swim time between 9 month-old rats OVX for 6
days and 15 month-old rats OVX for 6 months (OV). The swim
time of rats that started to receive estradiol 180 days after OVX
was 7168 sec (Figure 4B), no difference was observed with that in
15 month old sham-OVX and OVX rats. These findings suggest
that exogenous estradiol may serve as an anti-depressant agent in
rats when the estradiol is given soon after OVX, but not after
prolonged loss of ovarian hormones.
ERb2 expression in circulating white blood cells (WBC)
reflects the expression of ERb2 in hippocampus
If the ERb2 expression in circulating WBC correlates with that
in the hippocampus, then it will be a peripheral, easily accessible,
laboratory reference marker for ET prescription in clinic.
Therefore, we measured and compared ERb2 expression protein
extraction of the WBC from the whole blood and hippocampus by
Western blot. The results of Western blot analysis demonstrated
an increase in expression of ERb2, but not of ERb, in WBC of the
rats OVX for 6 days. Similar to the expression pattern of ERb2i n
hippocampus, Early ET also produced a reduction of expression
ERb2 in WBC of female rats (Figure 5A). The association of the
optical densities obtained from the WBC and hippocampus of
each samples were analyzed by Pearson Correlation as plotted in
Figure 5. The results indicated that the expression levels of ERb2
in WBC and hippocampus are highly associated (r=0.93, p,0.05)
in OVX rats that received vehicle (OV) or Early ET (OE)
(Figure 5B).
Discussion
The causes for the discrepant results from basic science studies
of the effects of estrogen therapy after ovarian hormone loss and
the results of the WHIMS trial are no doubt complex. Reanalyzes
of the WHIMS data, meta-analyses of early clinical trials, and
meta-analysis of studies of ET in bilateral oophorectomy [5], as
well as more recent prospective studies, support the theory of a
critical period or therapeutic window soon after menopause during
which time the initiation of estrogen therapy maintains normal
neural and cognitive functions, while initiation of ET well after
menopause is ineffective or harmful.
The molecular mechanisms for this window are unknown.
Recent studies suggest that the C terminus of Hsc70-interacting
protein (CHIP)-mediated degradation of hippocampal estrogen
receptor-a [37] may serve as a molecular mechanism for the
critical therapeutic window for post-menopausal ET [37,38]. We
present another potential mechanism, the increased expression of
the dominant negative ERb isoform, ERb2, which appears to be a
crucial determinant of the neuroprotective and neurogenic efficacy
of ET responsible, at least in part, for the loss of estrogen response
after protracted absence of ovarian hormones in a rat model of
menopause.
The 18-amino acid insertion of ERb2 lies within helix 6, a
structure immediately following the b-turn within the ligand
binding domain and in the center of the ligand binding pocket
[39]. Recombinant protein generated by in vitro transcription/
translation showed that ERb2 had markedly reduced ligand
binding (K(D)=17.7+/24.7 nM) compared with ERb bound
3H-
estradiol (K(D)=0.56+/20.19 nM) [40], demonstrating that the
18 amino acids insertion significantly alters the structure of the
ERb ligand binding pocket and impedes binding to ligands.
Because their DNA binding domains are the same, ERb2 and
ERb have similar binding affinity for palindromic estrogen
responsive elements (EREs) in vitro and in vivo [40]. ERb2 has
little transcriptional activity except at high ligand concentrations in
NIH 3T3 cells with transactivated ERE-tk-CAT reporter genes,
due to low ligand binding affinity. Co-transfected ERb2 has been
found to significantly inhibit the transcriptional activities of ERa
and ERb in several studies [22,25,40–42]. The most plausible
mechanism is that ERb2 competes as a homodimer or
heterodimer with the homodimers of ERa or ERb in binding to
ERE. Both human and rodent ERb2 forms heterodimers of ERa/
ERb2o rE R b/ERb2, as demonstrated by gel shift assay
[17,22,41], and the ERa/ERb2 heterodimer shows significantly
higher affinity to ERE than that of the homodimer of ERa [42].
Nuclear receptors form strong dimers that are essential for their
function as transcription factors and ligand binding affects dimer
stability. ER dimerization is ligand independent [43,44]. Un-
liganded ER-LBDs exist as stable dimers with a slow dissociation
rate (t1/2=3963 min at 28 C) which is further slowed (#7-fold)
by the addition of various ligands [45]. Dimerization of ERa and
ERb is E2- and antiestrogen (EM-652)-independent in human
embryo kidney 293 cells using the fluorescence resonance energy
transfer (FRET) technique [46] and bioluminescence resonance
Figure 5. Expression of ERb2 in white blood cells (WBC)
correlates with that in the Hippocampus. The expression of
ERb2 in peripheral blood WBC and hippocampus in rats that received
Early ET (OE) or vehicle (OV) was measured by Western blot. A. The
representative images of ERb2 Western blot of hippocampus and WBC.
B. Pearson correlation of the optical density of ERb2 protein expression
in extracts of hippocampus and peripheral leukocytes.
doi:10.1371/journal.pone.0033493.g005
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ERb2/ERb or ERb2/ERa are predicted to bind to E2 at least 30
times less [25,41,42], thus their transcriptional activity is similarly
reduced. Hence the efficacy of estradiol is diminished when
expression of ERb2 increases, as occurs after loss of ovarian
estrogen. While the hypothesis is that in the absence of E2 in the
rat and human the estrogen insensitive ERb2 accumulates and
obstructs normal function of the remaining ER [22,41,42], the
possibility of the accumulation of another ligand for ERb2 that
causes it to act as a repressor of normal ER function should not be
discounted [42].
The relevance of our rat model to the human after menopause
is based on the following. First, the human ERb2 and rat ERb2
are functionally comparable. Both hERb2 and rERb2 differ from
ERb in the ligand-binding domain, both exhibit similar dominant
negative function, and both form dimers with ERa or ERb
[18,25,26,47–50]. Second, estropause in rodent shares similarities
with human menopause. The rodent estrous cycle is 4–5 days
long, consisting of proestrus, estrus, diestrus I, and diestrus II. Rats
begin to show irregular cycles at 9–12 months, defined by
prolonged cycles, interspersed with the normal 4–5 days rhythm,
followed by a persistent acyclic, anestrus state with no ovulation
between 15 and 23 months of age [28,29]. Rat estropause differs
from monkey and human menopause in that aged rats retain a
much larger number of primary oocytes, resulting in higher
estrogen levels at the onset of persistent diestrus than those seen in
primates after menopause [28] [51,52]. To limit this difference,
the ovaries were removed from rats entering estropause, thus
providing a model that mimics both the age and ovarian hormone
status of the post menopausal woman. The female rats receiving
estradiol on day 7, or 181 after OVX at 9 months of age is
analogous to estrogen therapy in a human early and decades later
after menopause, respectively. The ages of the rats used, 6, 9 and
15 months, are thought to correspond with adult reproductive,
peri-menopasue, and late post-menopause in women.
In the current study ERb2 expression increased in the brains of
intact rats with age and estropause, natural ovarian failure, as well
as with ovariectomy. The progressive increase in ERb2 from 6, to
9 to 15 months of age in the sham control correlated with a
significant decrease in NPC proliferation in the hippocampus, as
well as swim time in a forced swim test. Similarly, Nerve growth
factor and brain Insulin-like Growth Factor decrease in with age
rats [53–56].
Loss of neurons and a decrease in NPC proliferation are
associated with depression and dementia, and preservation of NPC
proliferation is suggested as a mechanism for the antidepressant
effect of estrogen treatment after menopause and ovariectomy
[57–60]. Others and we have demonstrated a time dependent loss
of the effect of estradiol on NPC proliferation in dentate gyrus
SGZ in OVX rats [30,61]. Unbiased stereology in rats at 6 months
of age demonstrated that compared to the vehicle treated OVX
group, estradiol administration initiated 6 days after OVX
increased SGZ NPC proliferation by 40%, while ET initiated 28
days post-OVX had no significant effect on OVX-induced decline
of NPC proliferation [30,61]. Using a similar protocol, we used
unbiased steriology to measure BrdU positive cells in hippocampal
SGZ in rats in which ET was initiated 14 days after OVX and
observed a 13.2% increase in proliferation (unpublished data).
Ki-67 is an endogenous transient cell proliferating marker
expressed in nuclei of actively cycling and does not express in the
differentiating quiescent cells. In our previous study we observed a
43% increase in hippocampal cell proliferation upon estradiol
treatment of OVX rats by counting Ki-67 positive cell numbers
using flow cytometry [32]. While analysis by flow cytometry does
not determine the type of proliferating cell, this relative increase is
similar to the 40% increase of BrdU cells in SGZ in the estradiol
treated group reported in Tanapat’s study [30], suggesting that the
cell proliferation detected by Ki-67 positive cells in whole
hippocampus reflects the dividing potential of NPC in SGZ,
though proliferation of other cells may also be involved.
In the current study hippocampal cell proliferation and swim
time were not significantly different between intact 15-month-old
rats and those ovariectomized 6 months before at 9 months of age,
when ovarian function in rats normally declines. This suggests that
this model is appropriate for comparison to the WHIMS study in
which ET was initiated a decade or more after natural menopause
in many of the women. ET initiated 6 days after OVX in rats
reversed the decrease in hippocampal cell proliferation produced
by OVX, however ET initiated 180 days after OVX, a situation
analogous to initiating ET a decade or more after natural
menopause, did not.
In summary, our study confirmed and extended the evidence
for a consistent progressive increase in ERb2 associated with the
loss of ovarian hormones. The accumulation of the dominant
negative ERb2 correlated with duration of ovarian hormone loss
and the inability of ET to reverse the decrease in neuronal
proliferation and function and performance in the forced swim test
for depression in rats. Accelerated ERb2 expression and
accumulation in women may be a mechanism for the loss of
efficacy of estrogen therapy if treatment is delayed for too long
after menopause. Significant risks of ET in women have been
identified, particularly in those in which ET is initiated long after
menopause. Expression of ERb2 in circulating leukocytes
paralleled that in the brain, suggesting the potential for using
WBC ERb2 levels as a clinically useful biomarker to identify the
therapeutic window for effective ET. Measurement of ERb2
expression in peripheral WBC could provide a guide for when to
initiate post-menopausal estrogen therapy and to avoid therapy
when the risk/benefit ratio is unfavorable. Furthermore, determi-
nation of the factors leading to increased ERb2 expression could
lead to targeted non-estrogen therapies and/or expand the
therapeutic window and delay the depression and cognitive loss
that has been associated with menopause.
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